269 related articles for article (PubMed ID: 31400565)
21. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
Yang HM; Lou G
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
[No Abstract] [Full Text] [Related]
22. Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer.
Li Y; Zhang C; Ji R; Lu H; Zhang W; Li LL; Liu R; Qian H; He A
Int J Gynecol Cancer; 2020 Jan; 30(1):74-82. PubMed ID: 31822507
[TBL] [Abstract][Full Text] [Related]
23. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
[TBL] [Abstract][Full Text] [Related]
24. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
[TBL] [Abstract][Full Text] [Related]
25. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
Qin L; Huang H; Chen M; Liang Y; Wang H
J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
[TBL] [Abstract][Full Text] [Related]
26. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
[TBL] [Abstract][Full Text] [Related]
27. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
[TBL] [Abstract][Full Text] [Related]
28. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
[TBL] [Abstract][Full Text] [Related]
29. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
30. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
Zhao D; Wang X; Zhang W
BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
[TBL] [Abstract][Full Text] [Related]
31. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
Pradjatmo H; Pradjatmo H
Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
34. Serum CA125 in combination with ferritin improves diagnostic accuracy for epithelial ovarian cancer.
Zhao J; Guo N; Zhang L; Wang L
Br J Biomed Sci; 2018 Apr; 75(2):66-70. PubMed ID: 29452533
[TBL] [Abstract][Full Text] [Related]
35. Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers.
Jiang QX; Jiang YX; Wang X; Luo SJ; Zhou R; Linghu H
Clin Chim Acta; 2019 Aug; 495():148-153. PubMed ID: 30885671
[TBL] [Abstract][Full Text] [Related]
36. CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer.
Liao YC; Ou YC; Wu CH; Fu HC; Tsai CC; Lin H
Cancer Biomark; 2021; 32(4):559-567. PubMed ID: 34397404
[TBL] [Abstract][Full Text] [Related]
37. Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer.
Wang J; Liu Y; Li J; Lu X
J Obstet Gynaecol Res; 2019 May; 45(5):1006-1011. PubMed ID: 30687999
[TBL] [Abstract][Full Text] [Related]
38. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
39. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
40. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]